Recombinant group B streptococcus beta C protein and a variant with the deletion of its immunoglobulin A-binding site are protective mouse maternal vaccines and effective carriers in conjugate vaccines

被引:13
作者
Yang, Hsiao-Hui [1 ]
Madoff, Lawrence C. [1 ]
Guttormsen, Hilde-Kari [1 ]
Liu, Yong-Dong [1 ]
Paoletti, Lawrence C. [1 ]
机构
[1] Brigham & Womens Hosp, Harvard Med Sch, Dept Med, Channing Lab, Boston, MA 02115 USA
关键词
D O I
10.1128/IAI.00332-07
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Immunogenic vaccines against group B Streptococcus (GBS) have been created by coupling the GBS capsular polysaccharides (CPS) to carrier proteins. The GBS beta C protein (BCP) serves as an effective carrier while inducing protective immunity against BCP-expressing strains. BCP also binds human immunoglobulin A (IgA), a characteristic that may be undesirable for use in humans. Here, we examined the immunogenicity and protective efficacy of a recombinant GBS BCP (rBCP), an rBCP modified to eliminate its IgA-binding site (rBCP(Delta IgA)), and their corresponding GBS serotype III CPS conjugates (III-rBCP and III-rBCP(Delta IgA)). Deletion of the IgA-binding site or conjugation to CPS did not alter antigenic BCP epitopes. Recombinant proteins and conjugates elicited specific, high-titered IgG in mice. Antisera to rBCP, rBCPA(Delta IgA), III-rBCP, and III-rBCP(Delta IgA) opsonized GBS strains A909 (Ia/BCP+) and H36B (Ib/BCP+) for killing by HL-60 cells; antiserum to III-rBCP and III-rBCP(Delta IgA) also opsonized strain M781 (III/BCP-). Vaccination of female mice with either rBCP or rBCP(Delta IgA) protected similar to 40% of their pups challenged with GBS strain A909. Pups born to III-rBCP- or III-rBCP(Delta IgA)-vaceinated dams survived at rates of 56% and 66%, respectively. Over 90% of pups born to dams that received the type III CPS conjugates survived challenge with GBS strain M781. In summary, rBCP and rBCP(Delta IgA) proteins and the conjugates containing them were immunogenic in mice, inducing both CPS- and protein-specific functional IgG. These results suggest that the rBCP(Delta IgA) could be used as a carrier to augment the immunogenicity of the CPS while expanding coverage to GBS strains bearing BCP.
引用
收藏
页码:3455 / 3461
页数:7
相关论文
共 36 条
  • [1] Streptococcal β protein has separate binding sites for human factor H and IgA-Fc
    Areschoug, T
    Stålhammar-Carlemalm, M
    Karlsson, I
    Lindahl, G
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (15) : 12642 - 12648
  • [2] IMMUNIZATION OF PREGNANT-WOMEN WITH A POLYSACCHARIDE VACCINE OF GROUP-B STREPTOCOCCUS
    BAKER, CJ
    RENCH, MA
    EDWARDS, MS
    CARPENTER, RJ
    HAYS, BM
    KASPER, DL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1988, 319 (18) : 1180 - 1185
  • [3] Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines
    Baker, CJ
    Paoletti, LC
    Rench, MA
    Guttormsen, HK
    Edwards, MS
    Kasper, DL
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (06) : 1103 - 1112
  • [4] Group B streptococcal conjugate vaccines
    Baker, CJ
    Edwards, MS
    [J]. ARCHIVES OF DISEASE IN CHILDHOOD, 2003, 88 (05) : 375 - 378
  • [5] CORRELATION OF MATERNAL ANTIBODY DEFICIENCY WITH SUSCEPTIBILITY TO NEONATAL GROUP-B STREPTOCOCCAL INFECTION
    BAKER, CJ
    KASPER, DL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1976, 294 (14) : 753 - 756
  • [6] Identification of group B streptococcal Sip protein, which elicits cross-protective immunity
    Brodeur, BR
    Boyer, M
    Charlebois, I
    Hamel, J
    Couture, F
    Rioux, CR
    Martin, D
    [J]. INFECTION AND IMMUNITY, 2000, 68 (10) : 5610 - 5618
  • [7] Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P1
  • [8] Antibody against surface-bound C5a peptidase is opsonic and initiates macrophage killing of group B streptococci
    Cheng, Q
    Carlson, B
    Pillai, S
    Eby, R
    Edwards, L
    Olmsted, SB
    Cleary, P
    [J]. INFECTION AND IMMUNITY, 2001, 69 (04) : 2302 - 2308
  • [9] *CTR DIS CONTR PRE, 2006, ACT BACT COR SURV RE
  • [10] *CTR DIS CONTR PRE, 2004, MMWR-MORBID MORTAL W, V53, P502